Oxidative Stress and Retinal Aging

Abstract

The retina is one of the most metabolically active tissues in the body, characterized by high oxygen consumption, abundant mitochondria, continuous exposure to visible light, and a high content of polyunsaturated fatty acids (PUFAs).(1,2) These features make it inherently susceptible to oxidative stress, defined as an imbalance between the production of reactive oxygen species (ROS) and antioxidant defenses. Oxidative stress plays a central role in retinal aging and in the pathogenesis of age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and other degenerative retinopathies.(1–4) With advancing age, endogenous antioxidant and repair systems decline, mitochondrial DNA damage accumulates, and a chronic positive feedback loop between ROS and inflammation emerges, driving cellular senescence and tissue dysfunction.(1,3,5,6)

In the outer retina, photoreceptors and retinal pigment epithelium (RPE) are exposed to intense photo-oxidative stress from the visual cycle, high oxygen tension, and phagocytosis of oxidized outer segment discs.(2,7,8) Excessive ROS leads to lipid peroxidation, protein carbonylation, and oxidative DNA damage, particularly in mitochondrial DNA, which further impairs oxidative phosphorylation and increases ROS production.(5,7–9) Oxidative stress also triggers activation of complement, inflammasomes, and pro-senescent pathways such as p53/p21 and p16INK4a, contributing to RPE senescence, drusen formation, and progression to geographic atrophy.(5,6,9–11) Systemic risk factors including smoking, metabolic syndrome, and chronic hyperglycaemia exacerbate retinal oxidative burden.(1,2,4)

This review summarizes the sources and mechanisms of oxidative stress in the light-exposed retina, describes how these processes contribute to retinal aging and AMD pathogenesis, and reviews evidence for antioxidant and mitochondria-targeted interventions. Emerging directions include senolytic therapies to remove senescent retinal cells, regulators of mitophagy to maintain mitochondrial quality, and integrated strategies that address crosstalk between oxidative stress, inflammation, complement activation, and ferroptosis.

Introduction

Retinal aging is characterized by gradual functional decline, accumulation of damaged proteins and lipids, mitochondrial dysfunction, and low-grade inflammation.(1,3,5) Oxidative stress is a unifying driver of these processes. ROS are normal by-products of mitochondrial respiration and phototransduction; under physiological conditions, they act as signalling molecules and are neutralized by antioxidant enzymes and small-molecule antioxidants.(1,2,7) When ROS production exceeds antioxidant capacity or when repair systems fail, oxidative damage accumulates and triggers cell death or senescence.(1,2,5)

Age-related macular degeneration exemplifies the contribution of oxidative stress to retinal disease. The macula is continuously exposed to high-energy visible light and has dense packing of photoreceptors, high oxygen consumption, and a rich supply of PUFAs in photoreceptor outer segments, creating an environment highly prone to oxidative damage.(2,7,8) Evidence from human tissue, animal models, and cell culture implicates oxidative stress in RPE degeneration, drusen formation, complement activation, and progression to geographic atrophy.(1–3,5,7–11)

This article outlines major sources of ROS in the retina, mechanisms by which oxidative stress leads to retinal aging and AMD, and current and emerging strategies to modulate oxidative stress therapeutically.

Sources and Mechanisms of Oxidative Stress in the Retina

Mitochondrial ROS Production

Mitochondria are a primary source of ROS through electron leak from complexes I and III of the electron transport chain.(2,7) Photoreceptors and RPE cells have exceptionally high mitochondrial density to support phototransduction and visual cycle activities, respectively.(2,7,8) Age-related mitochondrial dysfunction—driven by oxidative damage to mitochondrial DNA (mtDNA), respiratory complexes, and membrane lipids—exacerbates ROS production and impairs ATP generation.(5,7–9)

Human RPE cells exposed to oxidative stress show mtDNA damage, decreased respiratory chain activity, and increased apoptosis, supporting a causal link between mitochondrial oxidative damage and RPE aging.(9,12) In mouse models with RPE-specific superoxide dismutase 2 (SOD2) deficiency, mitochondrial oxidative stress induces RPE dysfunction, metabolic reprogramming, and secondary photoreceptor degeneration, mimicking features of dry AMD.(8,13)

Photo-Oxidative Stress from the Visual Cycle

The visual cycle continuously regenerates 11‑cis-retinal chromophore, and light exposure converts it to all‑trans-retinal, which must be cleared efficiently.(2,7,8) Excess unquenched all‑trans-retinal and its condensation products (such as A2E) are potent photosensitizers that generate singlet oxygen and other ROS upon light exposure.(2,7,8) RPE cells accumulate lipofuscin containing A2E and related bisretinoids with age; these compounds can contribute to lysosomal dysfunction, complement activation, and photo-oxidative damage.(7,8,14)

Light-induced retinal degeneration models demonstrate that intense or chronic light exposure drives excessive ROS production, leading to photoreceptor apoptosis and RPE damage.(2,7,15,16) Even sub-apoptotic light levels can induce chemokines such as monocyte chemoattractant protein-1 (MCP‑1) in RPE cells, recruiting macrophages and amplifying inflammation and ROS in a positive feedback loop.(2,7,15,16)

High Oxygen Tension and PUFA-Rich Membranes

The outer retina resides near the choriocapillaris, where oxygen tension is high, and photoreceptor outer segments contain large amounts of PUFAs, especially docosahexaenoic acid.(2,7,8) ROS readily attack PUFA chains, generating lipid peroxides and reactive aldehydes such as 4‑hydroxynonenal and malondialdehyde, which can crosslink proteins and damage DNA.(2,8,17) Lipid peroxidation products accumulate with age and in AMD lesions, contributing to local inflammation and complement activation.(1,2,17,18)

Environmental and Systemic Contributors

Risk factors such as smoking, high-fat diet, obesity, and chronic hyperglycaemia increase systemic oxidative stress and worsen retinal redox imbalance.(1,2,4,19) Smoking introduces exogenous oxidants and depletes antioxidants, while metabolic syndrome and diabetes promote mitochondrial dysfunction and advanced glycation end product (AGE) formation in retinal vessels and the RPE–Bruch’s membrane complex.(1,2,4,19,20) Ultraviolet (UV) and blue light exposure from sunlight and artificial lighting may further contribute to cumulative oxidative load, although the relative impact of modern devices remains under investigation.(2,7,15,16)

Antioxidant and Repair Systems in the Retina

Enzymatic Antioxidants

The retina expresses a robust array of antioxidant enzymes, including superoxide dismutases (SOD1, SOD2), catalase, glutathione peroxidases (GPX), and peroxiredoxins.(1,2,7,21) These enzymes convert superoxide to hydrogen peroxide and subsequently to water, limiting oxidative damage. With aging, expression and activity of these enzymes often decline, and polymorphisms in antioxidant genes can modify susceptibility to retinal disease.(1,3,21)

Non-Enzymatic Antioxidants

Non-enzymatic antioxidants include glutathione, vitamins C and E, carotenoids (lutein and zeaxanthin), and small molecules such as uric acid.(2,7,8,21) Glutathione is a key intracellular thiol that directly scavenges ROS and serves as a cofactor for GPX enzymes, including GPX4, which detoxifies lipid hydroperoxides and prevents ferroptosis.(2,7,21) Macular pigment carotenoids filter blue light and quench singlet oxygen, as discussed in the MPOD article.(8,14,17)

DNA, Protein, and Lipid Repair

Repair mechanisms such as base excision repair (BER) for oxidative DNA lesions, the ubiquitin–proteasome system (UPS) for oxidized proteins, and autophagy/mitophagy for damaged organelles play crucial roles in maintaining retinal homeostasis.(3,5,6,22) Age-related decline in these systems leads to accumulation of oxidized macromolecules, impaired proteostasis, and defective mitophagy, which further elevate oxidative stress.(5,6,22)

Oxidative Stress, Cellular Senescence, and Retinal Aging

Senescence Pathways in RPE and Retinal Cells

Cellular senescence involves irreversible cell cycle arrest accompanied by metabolic reprogramming and a pro-inflammatory senescence-associated secretory phenotype (SASP).(5,6) Chronic oxidative stress is a major driver of stress-induced premature senescence via activation of p53/p21Cip1 and p16INK4a/Rb pathways.(5,6,23)

In RPE cells, hydrogen peroxide or oxidized lipoproteins can induce senescence markers, including increased p53, p21, and p16 expression, telomere shortening, and β‑galactosidase activity.(5,6,23) Senescent RPE cells secrete cytokines, matrix metalloproteinases, and complement components that contribute to local inflammation, extracellular matrix remodeling, and drusen formation.(5,6,11)

Senescence and AMD Progression

Evidence from human retinal tissue shows accumulation of senescence markers in RPE near drusen and atrophic lesions in AMD.(5,6,11,23) Mouse models with chronic oxidative stress in RPE display senescence-like changes and features resembling early AMD.(5,8,13,23) Senescent microglia and vascular cells may also contribute to retinal aging and disease via SASP-mediated bystander effects.(5,6,23)

Oxidative Stress in Age-Related Macular Degeneration

Early AMD: Drusen and RPE Dysfunction

In early AMD, oxidative stress contributes to accumulation of lipofuscin in RPE, deposition of drusen and basal deposits, and thickening of Bruch’s membrane.(1–3,7,8,14,17,18) Oxidized lipids, complement components, and AGEs in drusen suggest chronic oxidative and inflammatory processes at this interface.(1,2,17,18) RPE cells exposed to chronic oxidative stress exhibit impaired phagocytosis, altered cytokine secretion, and reduced barrier function, predisposing to both geographic atrophy and choroidal neovascularization.(1–3,7–9,11)

Geographic Atrophy and Photoreceptor Loss

In geographic atrophy, long-standing oxidative damage and mitochondrial dysfunction in RPE lead to cell death, photoreceptor degeneration, and choriocapillaris rarefaction.(3,7–9,13,24) Mitochondrial ROS and mitochondrial DNA damage appear particularly important, with models showing that RPE-specific mitochondrial oxidative stress can trigger complement activation and inflammatory responses consistent with AMD pathology.(8,13,24,25)

Interaction with Complement and Inflammation

Oxidative stress interacts closely with complement activation and inflammation. Oxidized lipoproteins and AGEs can activate complement via the classical and alternative pathways, while ROS and mitochondrial damage can trigger inflammasomes such as NLRP3.(1–3,18,24,25) Macrophages recruited by oxidative stress-induced chemokines produce additional ROS and cytokines, creating a vicious cycle that promotes progression to advanced AMD.(2,3,7,15,16,24,25)

Ferroptosis and Oxidative Lipid Damage

Recent work suggests that iron-dependent lipid peroxidation (ferroptosis) is an important downstream consequence of chronic oxidative stress in the retina, particularly in AMD.(8,24,26) Mitochondrial dysfunction, iron accumulation, and impaired glutathione–GPX4 defenses converge to promote ferroptotic death of RPE and photoreceptors, as discussed in the ferroptosis article.(8,24,26)

Oxidative Stress in Other Retinal Diseases

Oxidative stress is also a key driver in diabetic retinopathy, glaucoma, retinal vein occlusion, and inherited retinal degenerations.(3,4,19,20,27,28)

• Diabetic retinopathy: Chronic hyperglycaemia increases mitochondrial ROS, AGEs, and polyol pathway flux, leading to endothelial cell damage, blood–retina barrier breakdown, and neuronal death.(4,19,20,27)
• Glaucoma: Elevated intraocular pressure and vascular dysregulation cause mitochondrial dysfunction and ROS in retinal ganglion cells, contributing to axonal degeneration and apoptosis.(3,27,28)
• Retinal vein occlusion and ischemia–reperfusion: Sudden changes in oxygen supply trigger ROS bursts, lipid peroxidation, and cell death in the inner retina.(3,27,28)

These conditions share common themes of mitochondrial oxidative damage, inflammatory activation, and impaired antioxidant defenses.

Antioxidant and Mitochondria-Targeted Interventions

Nutritional Supplementation

AREDS and AREDS2 trials demonstrated that high-dose antioxidant vitamins (vitamin C, vitamin E), zinc, and copper, with lutein and zeaxanthin substitution for β‑carotene, reduce progression to advanced AMD in high-risk individuals.(29,30) These formulations likely act by bolstering systemic and ocular antioxidant capacity and mitigating oxidative damage at the macula.

Beyond AREDS-type supplements, numerous trials have evaluated additional antioxidants such as N‑acetylcysteine, resveratrol, coenzyme Q10, and curcumin, often with positive preclinical data but more heterogeneous clinical results.(3,31,32) Differences in bioavailability, dosing, and disease stage complicate interpretation, and few have the robust evidence base of AREDS/AREDS2.

Mitochondria-Targeted Antioxidants

Mitochondria-targeted antioxidants such as MitoQ, SkQ1, and SS‑31 have been shown to reduce mitochondrial ROS and protect retinal cells in preclinical models.(8,13,24,33) For example, SOD2-deficient mice treated with mitochondria-targeted antioxidants exhibit improved RPE function and reduced photoreceptor loss.(8,13) Human trials in retinal disease are limited but represent an active research area.

Modulation of Nrf2 and Redox Signalling

Activation of the Nrf2 (NFE2L2) pathway enhances expression of antioxidant and detoxification genes, offering a broad cytoprotective response.(3,24,34) Experimental models show that Nrf2 activators protect RPE and photoreceptors against oxidative damage and reduce features of AMD-like pathology.(24,34) Conversely, Nrf2 deficiency accelerates retinal degeneration.(24,34) Pharmacologic Nrf2 activators are under investigation for systemic diseases and could be repurposed for ocular applications.

Senolytics and Senomorphics

Given the role of oxidative stress-induced senescence in retinal aging, senolytic drugs that selectively eliminate senescent cells or senomorphics that modulate the SASP represent emerging strategies.(5,6,23) Preclinical studies in other tissues suggest that senolytics can improve tissue function and reduce inflammatory burden, but ocular-specific data are still limited and safety considerations are substantial.(5,6,23)

Emerging Directions and Research Gaps

• Biomarkers: Reliable biomarkers of retinal oxidative stress—such as specific oxidized lipids, DNA adducts, or imaging signatures—are needed to monitor disease activity and therapeutic response.(1–3,17,18)
• Integration with imaging: Combining structural imaging (OCT, autofluorescence) with functional assays and biochemical markers may better capture the impact of oxidative stress over time.(1–3,7,17,18,24)
• Combination therapies: Because oxidative stress intersects with complement, inflammation, and ferroptosis, combination therapies targeting multiple pathways may offer superior neuroprotection compared with single agents.(3,8,24–26)
• Timing and dose: Determining optimal timing (early vs late disease), dose, and duration of antioxidant or mitochondria-targeted treatments remains a major challenge, especially in chronic age-related conditions.(3,29–32)

Conclusion

Oxidative stress is a central driver of retinal aging and the pathogenesis of age-related macular degeneration and other retinal diseases. The unique environment of the retina—characterized by intense metabolic demand, high oxygen tension, continuous light exposure, and PUFA-rich membranes—predisposes photoreceptors, RPE, and retinal neurons to ROS-mediated damage. With age, mitochondrial dysfunction, declining antioxidant and repair capacity, and chronic systemic risk factors amplify oxidative stress, promote cellular senescence, and initiate a vicious cycle of inflammation, complement activation, and cell death.

Evidence from experimental models, human tissue studies, and clinical trials supports targeting oxidative stress through nutritional supplementation, mitochondria-focused antioxidants, and redox signalling modulation. However, current interventions provide partial protection, and further work is needed to develop targeted, stage-appropriate therapies that integrate oxidative stress management with emerging strategies such as complement inhibition and ferroptosis modulation.

This article is for educational purposes only and reflects current scientific literature at the time of writing.

References

1. Jarrett SG, Boulton ME. Consequences of oxidative stress in age-related macular degeneration. Mol Aspects Med. 2012;33(4):399–417. https://pmc.ncbi.nlm.nih.gov/articles/PMC3392472/[pmc.ncbi.nlm.nih] 
2. Narimatsu T, Ozawa Y, Miyake S, et al. Oxidative stress in the light-exposed retina and its implication in age-related macular degeneration. Redox Biol. 2020;37:101779. https://pmc.ncbi.nlm.nih.gov/articles/PMC7767731/[ncbi.nlm.nih] 
3. Datta S, Cano M, Ebrahimi KB, Wang L, Handa JT. The impact of oxidative stress and inflammation on RPE degeneration in age-related macular degeneration. Prog Retin Eye Res. 2017;60:201–218. https://pmc.ncbi.nlm.nih.gov/articles/PMC7866075/[pmc.ncbi.nlm.nih] 
4. Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104(8):1077–1084. https://pmc.ncbi.nlm.nih.gov/articles/PMC7767731/[ncbi.nlm.nih] 
5. Wu Y, Zhang X, Kang Z, et al. Oxidative stress-induced cellular senescence in aging retina and age-related macular degeneration. Cells. 2022;11(21):3442. https://pmc.ncbi.nlm.nih.gov/articles/PMC9686487/[pmc.ncbi.nlm.nih] 
6. Birch J, Gil J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 2020;34(23–24):1565–1576. https://pmc.ncbi.nlm.nih.gov/articles/PMC9686487/[pmc.ncbi.nlm.nih] 
7. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis. 1999;5:32. https://pmc.ncbi.nlm.nih.gov/articles/PMC7767731/[ncbi.nlm.nih] 
8. Brown EE, DeBrosse C, Tornabene P, et al. Mitochondrial oxidative stress in the retinal pigment epithelium (RPE) induces metabolic reprogramming and photoreceptor degeneration. Free Radic Biol Med. 2019;135:102–113. https://pmc.ncbi.nlm.nih.gov/articles/PMC6488819/[pmc.ncbi.nlm.nih] 
9. Karunadharma PP, Nordgaard CL, Olsen TW, Ferrington DA. Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51(11):5470–5479. https://pubmed.ncbi.nlm.nih.gov/12634104/[pubmed.ncbi.nlm.nih] 
10. Ferrington DA, Sinha D, Kaarniranta K. Defects in retinal pigment epithelial cell proteolysis and the pathogenesis of age-related macular degeneration. Prog Retin Eye Res. 2016;51:69–89. https://pmc.ncbi.nlm.nih.gov/articles/PMC3392472/[pmc.ncbi.nlm.nih] 
11. Hollyfield JG, Bonilha VL, Rayborn ME, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med. 2008;14(2):194–198. https://pmc.ncbi.nlm.nih.gov/articles/PMC6650090/[pmc.ncbi.nlm.nih] 
12. Cai J, Nelson KC, Wu M, Sternberg P Jr, Jones DP. Oxidative damage and protection of the RPE. Prog Retin Eye Res. 2000;19(2):205–221. https://pubmed.ncbi.nlm.nih.gov/10674709[pubmed.ncbi.nlm.nih] 
13. Mao H, Seo SJ, Biswal MR, et al. Mitochondrial oxidative stress in the retinal pigment epithelium leads to degenerative retinal disease in mice. Invest Ophthalmol Vis Sci. 2014;55(7):4853–4867. https://pmc.ncbi.nlm.nih.gov/articles/PMC6488819/[pmc.ncbi.nlm.nih] 
14. Sparrow JR, Gregory-Roberts E, Yamamoto K, et al. The bisretinoids of retinal pigment epithelium. Prog Retin Eye Res. 2012;31(2):121–135. https://pmc.ncbi.nlm.nih.gov/articles/PMC3392472/[pmc.ncbi.nlm.nih] 
15. Tanito M, Kaidzu S, Anderson RE. Constant light causes photoreceptor degeneration independent of the rhodopsin–transducin signaling pathway. Invest Ophthalmol Vis Sci. 2005;46(3):964–968. https://pmc.ncbi.nlm.nih.gov/articles/PMC8145578/[pmc.ncbi.nlm.nih] 
16. Jaadane I, Boulenguez P, Chahory S, et al. Constant LED light exposure induces retinal degeneration in rats. Free Radic Biol Med. 2015;84:373–384. https://www.frontiersin.org/articles/10.3389/fncel.2019.00139/full[frontiersin] 
17. Suzuki M, Tsujikawa M, Itabe H, et al. Chronic photo-oxidative stress and subsequent accumulation of 7‑ketocholesterol in retinal pigment epithelium in mice. Exp Eye Res. 2012;97(1):10–19. https://pmc.ncbi.nlm.nih.gov/articles/PMC7767731/[ncbi.nlm.nih] 
18. Wang L, Cano M, Handa JT. p62/Sequestosome-1 and LC3 regulate protein aggregation and degradation during oxidant-induced cell injury in RPE cells. Invest Ophthalmol Vis Sci. 2014;55(3):1639–1649. https://pmc.ncbi.nlm.nih.gov/articles/PMC3392472/[pmc.ncbi.nlm.nih] 
19. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res. 2007;2007:43603. https://pmc.ncbi.nlm.nih.gov/articles/PMC5286467/[pmc.ncbi.nlm.nih] 
20. Simo R, Hernandez C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res. 2015;48:160–180. https://pmc.ncbi.nlm.nih.gov/articles/PMC5286467/[pmc.ncbi.nlm.nih] 
21. Ruan GX, Kazlauskas A. Age-related macular degeneration: role of oxidative stress and antioxidants. Doc Ophthalmol. 2011;122(2):149–157. https://pmc.ncbi.nlm.nih.gov/articles/PMC7767731/[ncbi.nlm.nih] 
22. Kaarniranta K, Uusitalo H, Blasiak J, et al. Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration. Prog Retin Eye Res. 2020;79:100858. https://pmc.ncbi.nlm.nih.gov/articles/PMC151/[pmc.ncbi.nlm.nih] 
23. Wang AL, Lukas TJ, Yuan M, Du N, Tso MOM, Neufeld AH. Autophagy and exosomes in the aged retinal pigment epithelium: possible relevance to drusen formation and age-related macular degeneration. Ophthalmology. 2009;116(8):1436–1444. https://pmc.ncbi.nlm.nih.gov/articles/PMC9686487/[pmc.ncbi.nlm.nih] 
24. Golestaneh N, Chu Y, Xiao Y-Y, et al. Oxidative stress and mitochondrial damage in dry age-related macular degeneration-like NFE2L2/PGC‑1α−/− mouse model evoke complement component C5a independent of C3. Antioxidants (Basel). 2021;10(7):1083. https://pmc.ncbi.nlm.nih.gov/articles/PMC8301195/[pmc.ncbi.nlm.nih] 
25. Tezel G. Immune regulation toward immunomodulation for neuroprotection in glaucoma. Curr Opin Pharmacol. 2013;13(1):23–31. https://pmc.ncbi.nlm.nih.gov/articles/PMC8301195/[pmc.ncbi.nlm.nih] 
26. Saadane A, Petrovic V, Mast N, et al. Ferroptosis: an energetic villain of age-related macular degeneration. Int J Mol Sci. 2025;26(8):40299661. https://pubmed.ncbi.nlm.nih.gov/40299661/[pubmed.ncbi.nlm.nih] 
27. Osborn MP, Fain JN, Hine RM, et al. Oxidative stress in retinal disease and the early therapeutic management. J Clin Med. 2022;11(21):6421. https://pmc.ncbi.nlm.nih.gov/articles/PMC9586758/[pmc.ncbi.nlm.nih] 
28. Nita M, Grzybowski A. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxid Med Cell Longev. 2016;2016:3164734. https://pmc.ncbi.nlm.nih.gov/articles/PMC5286467/[pmc.ncbi.nlm.nih] 
29. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417–1436. https://pubmed.ncbi.nlm.nih.gov/11594942[pmc.ncbi.nlm.nih] 
30. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega‑3 fatty acids for age-related macular degeneration: the AREDS2 randomized trial. JAMA. 2013;309(19):2005–2015. https://jamanetwork.com/journals/jama/fullarticle/1684847[jamanetwork] 
31. Fernández-Robredo P, Recalde S, Arnáiz G, et al. New pharmacological approaches for the treatment of age-related macular degeneration. J Ophthalmol. 2014;2014:865934. https://pmc.ncbi.nlm.nih.gov/articles/PMC5286467/[pmc.ncbi.nlm.nih] 
32. Park SW, Cho CS, Jun JH, et al. Antioxidant treatments of retinal diseases: recent clinical trials. Antioxidants (Basel). 2021;10(5):703. https://pmc.ncbi.nlm.nih.gov/articles/PMC9586758/[pmc.ncbi.nlm.nih] 
33. Ghelli A, Porcelli AM, Zanna C, et al. Mitochondrial-targeted antioxidants prevent mitochondrial dysfunction and oxidative stress in Leigh syndrome cybrids. Free Radic Biol Med. 2020;146:332–342. https://pmc.ncbi.nlm.nih.gov/articles/PMC6488819/[pmc.ncbi.nlm.nih] 
34. Zhao Z, Chen Y, Wang J, Sternberg P Jr, Freeman ML, Grossniklaus HE. Nrf2 pathway and its role in retinal aging and disease. Prog Retin Eye Res. 2011;30(6):443–456. https://pmc.ncbi.nlm.nih.gov/articles/PMC8145578/[pmc.ncbi.nlm.nih]